Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma
暂无分享,去创建一个
C. Rodríguez | T. Martín | A. Gómez | J. Cruz | A. Olaverri | M. Hernandez
[1] M. Secic,et al. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. , 2001, Cancer.
[2] P. Heenan,et al. Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis , 2001, Cancer.
[3] K. Hirakawa,et al. Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2000, Cancer.
[4] C. Robson,et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. , 1998, Cytometry.
[5] J. Thompson,et al. Cutaneous melanomas that defy conventional prognostic indicators. , 1996, Seminars in oncology.
[6] M. Berwick,et al. Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study , 1996, Cancer.
[7] Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Huang,et al. A prospective study of hypothalamus pituitary function after cranial irradiation with or without radiosensitizing chemotherapy , 1994, Journal of endocrinological investigation.
[9] J. Daurès,et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.
[10] K. Lam,et al. Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. , 1991, The Quarterly journal of medicine.
[11] T. Huang,et al. Early effects of cranial irradiation on hypothalamic pituitary function. , 1990, Journal of the Formosan Medical Association = Taiwan yi zhi.
[12] M. Huang,et al. Prospective hormone study of hypothalamic-pituitary function in patients with nasopharyngeal carcinoma after high dose irradiation. , 1989, Japanese journal of clinical oncology.
[13] C. Holman,et al. Inter‐observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia , 1984, Histopathology.
[14] W. Clark,et al. The classification of malignant melanoma and its histologic reporting , 1973, Cancer.
[15] W. Clark,et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.
[16] B. C. Tan,et al. Hypopituitary dwarfism following radiotherapy for nasopharyngeal carcinoma. , 1966, Clinical radiology.
[17] A. Stout,et al. Atlas of Tumor Pathology , 1954, American journal of clinical pathology.